Thrombolytic therapy for central venous catheter occlusion
Related Experiment Video
Updated: May 26, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
Published on: June 4, 2021
Jacquelyn L Baskin1, Ulrike Reiss, Judith A Wilimas
1Division of Hematology and Oncology, Children’s Hospital Los Angeles, Los Angeles, CA 90027, USA. jbaskin13@hotmail.com
Insights
Thrombolytic agents effectively clear central venous catheter obstructions. Newer medications show promise for faster and more effective treatment of these common catheter complications.
Area of Science:
- Vascular Access Management
- Pharmacological Interventions
- Medical Device Complications
Background:
- Central venous catheters (CVCs) are vital for chronic illness care but prone to obstructions.
- Catheter obstructions can delay critical treatments and necessitate device removal.
Purpose of the Study:
- To review the efficacy of thrombolytic therapy for central venous catheter obstruction.
- To assess clearance rates and time to clearance for various thrombolytic agents.
Main Methods:
- Literature review of Medline searches for central venous catheter obstruction and thrombolytic treatment.
- Assessment of thrombolytic therapy efficacy, clearance rates, and time to clearance.
Main Results:
- Alteplase achieves 86% overall clearance; newer agents like reteplase (95%), tenecteplase (83%), and alfimeprase (80%) show high efficacy.
- Recombinant urokinase demonstrated 73% overall clearance and reduced occlusion incidence (4-23%) with prophylactic use.
- Alfimeprase provided rapid clearance, resolving 40% of occlusions within 5 minutes.
Conclusions:
- Thrombolytic agents are effective in resolving most central venous catheter occlusions.
- Emerging thrombolytic agents may offer superior speed and efficacy compared to current options.
- Further randomized comparative studies are required to establish optimal thrombolytic management strategies.
Background:
Long-term central venous catheters have improved the quality of care for patients with chronic illnesses, but are complicated by obstructions which can result in delay of treatment or catheter removal.
Design And Methods:
This paper reviews thrombolytic treatment for catheter obstruction. Literature from Medline searches using the terms "central venous catheter", "central venous access device" OR "central venous line" associated with the terms "obstruction", "occlusion" OR "thrombolytic" was reviewed. Efficacy of thrombolytic therapy, central venous catheter clearance rates and time to clearance were assessed.
Results:
Alteplase, one of the current therapies, clears 52% of obstructed catheters within 30 min with 86% overall clearance (after 2 doses, when necessary). However, newer medications may have higher efficacy or shorter time to clearance. Reteplase cleared 67-74% within 30-40 min and 95% of catheters overall. Occlusions were resolved in 70 and 83% of patients with one and 2 doses of tenecteplase, respectively. Recombinant urokinase cleared 60% of catheters at 30 min and 73% overall. Alfimeprase demonstrated rapid catheter clearance with resolution in 40% of subjects within 5 min, 60% within 30 min, and 80% within 2 h. Additionally, urokinase prophylaxis decreased the incidence of catheter occlusions from 16-68% in the control group to 4-23% in the treatment group; in some studies, rates of catheter infections were also decreased in the urokinase group.
Conclusions:
Thrombolytic agents successfully clear central venous catheter occlusions in most cases. Newer agents may act more rapidly and effectively than currently utilized therapies, but randomized studies with direct comparisons of these agents are needed to determine optimal management for catheter obstruction.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Venous Thrombosis IV: Nursing Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
Peripheral Artery Disease III: Interprofessional Care

